Article

Sotrovimab retains activity against SARS-CoV-2 Omicron variant BQ.1.1 in a non-human primate model

2023-02-15

Abstract excerpt

The SARS-CoV2 Omicron variants have acquired new Spike mutations leading to escape from the most of the currently available monoclonal antibody treatments reducing the options for patients suffering from severe Covid-19. Recently, both in vitro and in vivo data have suggested that Sotrovimab could retain partial activity against recent omicron sub-lineage such as BA.5 variants, including BQ.1.1. Here we report f...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5b9252be-fe3a-5e7b-9a87-bc8463260229
DOI: 10.1101/2023.02.15.528538

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Sotrovimab retains activity against SARS-CoV-2 Omicron variant BQ.1.1 in a non-human primate modelDOI 10.1101/2023.02.15.528538Read

Sotrovimab Retains Activity Against SARS-CoV-2 Omicron Variant BQ.1.1 in a Nonhuman Primate ModelSemantic proximity Read

Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineagesSemantic proximity Read

Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 VariantsSemantic proximity Read

Preclinial Safety and Efficacy of a Therapeutic Antibody That Targets SARS-CoV-2 at the Sotrovimab Face But is Escaped by OmicronSemantic proximity Read

Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature reviewSemantic proximity Read

Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster modelSemantic proximity Read

Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster modelSemantic proximity Read

Sotrovimab drives SARS-CoV-2 Omicron variant evolution in immunocompromised patientsSemantic proximity Read

<i>In vivo</i> virological efficacy of monoclonal antibodies and direct antiviral agents against the SARS-CoV-2 BA.1 and BA.2 Omicron sublineagesSemantic proximity Read

High incidence of sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the SARS-CoV-2 Omicron variantSemantic proximity Read

In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5Semantic proximity Read

In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolateSemantic proximity Read